Actively Recruiting
FINE-REAL Korea: Observational Study on Finerenone Use in Chronic Kidney Disease and Type 2 Diabetes in Routine Care in South Korea
Led by Bayer · Updated on 2026-05-18
500
Participants Needed
1
Research Sites
17 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are studying people with chronic kidney disease (CKD) and type 2 diabetes (T2D) who are starting treatment with the drug finerenone. CKD is a condition where the kidneys slowly lose their ability to filter waste, and T2D is a condition where the body does not use insulin properly, which can harm the kidneys. This observational study aims to learn more about the characteristics and treatment patterns of patients with CKD and T2D receiving finerenone in routine medical care in South Korea. The study collects data from people newly prescribed finerenone as part of their usual treatment. Finerenone works by blocking certain proteins that can damage the kidneys and heart. Researchers will gather information on why finerenone was started or stopped, how long patients stay on treatment, the dosing details, and other medications taken alongside finerenone. The study also monitors any medical problems participants experience, including a focus on high potassium levels (hyperkalemia) and its effects, such as early stopping of treatment, dialysis, or hospital visits. Participants will be followed for up to 12 months or until they stop finerenone early. Data will be collected during routine medical visits through medical records and interviews. Researchers will analyze clinical features, treatment reasons, dosing, and adverse events during this period to better understand finerenone use in this patient group.
CONDITIONS
Brief Title
An Observational Study Called FINE-REAL Korea to Learn More About the Use of the Drug Finerenone in People With Chronic Kidney Disease and Type 2 Diabetes in a Routine Medical Care Setting in South Korea
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adult female or male participant aged 18 years or older
- Diagnosed with chronic kidney disease associated with type 2 diabetes by a physician
- Starting finerenone treatment within 8 weeks before or after signing the consent form
- Decision to start finerenone treatment made before signing the consent form
You will not qualify if you...
- Currently participating or participated previously in any investigational trial during this study
- Having contraindications to finerenone according to the local product label
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 screening and enrollment visit
Duration - Up to 12 months after start of finerenone
Participants who are newly prescribed finerenone under routine treatment conditions are observed to collect clinical data and treatment details.
Regular visits as part of routine medical care
Duration - Up to 30 days after the final treatment with finerenone
Participants are monitored for adverse events and safety outcomes after completing finerenone treatment.
1 to 2 follow-up visits depending on treatment completion
Trial Site Locations
Total: 1 location
1
Many Locations
Multiple Locations, South Korea
Actively Recruiting
Research Team
B
Bayer Clinical Trials Contact
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here